Literature DB >> 3910496

Biological potency of porcine, bovine and human insulins in the rabbit bioassay system.

M Pingel, A Vølund, E Sørensen, J E Collins, C T Dieter.   

Abstract

Potency determination of porcine, bovine and human insulins relative to the International Standard in the pharmacopoeial rabbit bioassay system requires that the log-dose response curves are parallel. Furthermore, the same relative potency should be obtained independent of how the hypoglycaemic response is defined. The results of 508 rabbit blood glucose assays have been analyzed by new multivariate statistical methods. No deviations from parallelism of the log-dose response curves were detected. However, the potencies showed significant variation depending on the blood sampling times. Pure porcine and human (semisynthetic and biosynthetic) insulin potencies decreased by 12% and 18%, respectively, from the 30-min to the 2.5-h response, whereas bovine insulin potencies increased by 9%. Since the standard is a 52:48 mixture of bovine and porcine insulins, these results could be due to porcine and human insulins having a quicker onset and shorter duration of hypoglycaemic effect than bovine insulin. This was confirmed in assays of bovine relative to porcine insulin and by direct comparison of mean blood glucose curves. It is concluded that there is a response time-dependent variation in potency when the test and standard insulin have a different species composition. Hence, pure species insulin standards - a porcine, a bovine and a human standard - are needed for assay of the three insulins.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3910496     DOI: 10.1007/bf00291079

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  20 in total

1.  Continuous-flow analysis for glucose, triglycerides, and ATP with immobilized enzymes in tubular form.

Authors:  L P León; M Sansur; L R Snyder; C Horvath
Journal:  Clin Chem       Date:  1977-09       Impact factor: 8.327

2.  Clinical aspects of insulin--antigenicity.

Authors:  J Schlichtkrull; J Brange; A H Christiansen; O Hallund; L G Heding; K H Jorgensen
Journal:  Diabetes       Date:  1972       Impact factor: 9.461

Review 3.  Human insulin.

Authors:  P D Home; K G Alberti
Journal:  Clin Endocrinol Metab       Date:  1982-07

4.  Multivariate bioassay.

Authors:  A Vølund
Journal:  Biometrics       Date:  1980-06       Impact factor: 2.571

5.  The Fourth International Standard for insulin.

Authors:  D R BANGHAM; M V MUSSETT
Journal:  Bull World Health Organ       Date:  1959       Impact factor: 9.408

6.  Somatostatin-like immunoreactivity in man. Measurement in peripheral plasma.

Authors:  B Tronier; U D Larsen
Journal:  Diabete Metab       Date:  1982-03

7.  Pharmacokinetics of subcutaneously administered human, porcine and bovine neutral soluble insulin to normal man.

Authors:  D R Owens; M K Jones; A J Birtwell; C T Burge; I R Jones; P J Heyburn; T M Hayes; L G Heding
Journal:  Horm Metab Res       Date:  1984-12       Impact factor: 2.936

8.  Chemical, physical, and biologic properties of biosynthetic human insulin.

Authors:  R E Chance; E P Kroeff; J A Hoffmann; B H Frank
Journal:  Diabetes Care       Date:  1981 Mar-Apr       Impact factor: 19.112

9.  Subcutaneous use of regular human insulin (Novo): pharmacokinetics and continuous insulin infusion therapy.

Authors:  G E Sonnenberg; F W Kemmer; H J Cüppers; M Berger
Journal:  Diabetes Care       Date:  1983 Mar-Apr       Impact factor: 19.112

10.  Comparison of potency of porcine insulin and semisynthetic human insulin at 3 dose levels using the euglycaemic clamp.

Authors:  D J Chisholm; E W Kraegen; M J Hewett; L Lazarus
Journal:  Horm Metab Res       Date:  1983-09       Impact factor: 2.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.